Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mesothelioma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    119 result(s) found for: Mesothelioma. Displaying page 4 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2016-002286-60 Sponsor Protocol Number: IND.227 Start Date*: 2019-08-01
    Sponsor Name:IFCT
    Full Title: A PHASE II/III RANDOMIZED STUDY OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA
    Medical condition: ADVANCED MALIGNANT PLEURAL MESOTHELIOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005621-24 Sponsor Protocol Number: N14PLU Start Date*: 2014-07-17
    Sponsor Name:Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
    Full Title: PeRsOnalized treatment fOr patients with pleural eFfusions due to malignant pleural mesothelioma or lung cancer in second or third line. An open label phase II study (Acronym: the PROOF study)
    Medical condition: Proven pleural effusion of malignant pleural mesothelioma or non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10066490 Progression of non-small cell lung cancer LLT
    17.0 100000004864 10027408 Mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005642-59 Sponsor Protocol Number: AK-2015-LC-1 Start Date*: 2016-02-23
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET
    Full Title: Phase II trial: uPAR-PET for prognostication in patients with non-small cell lung cancer and large cell neuroendocrine carcinoma of the lung
    Medical condition: Non-small cell lung cancer and large cell neuroendocrine carcinoma of the lung
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004420-39 Sponsor Protocol Number: 05-10 Start Date*: 2006-05-18
    Sponsor Name:All-Ireland Co-operative Oncology Research Group (ICORG)
    Full Title: An Open Label Phase II Multicentre Clinical Trial of Single Agent VELCADE (Bortezomib) in Patients with Malignant Pleural Mesothelioma
    Medical condition: Malignant Pleural Mesothelioma (in first line, and second line treatment settings)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) GB (Completed) BE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-003650-88 Sponsor Protocol Number: BAY94-9343/15743 Start Date*: 2015-11-25
    Sponsor Name:Bayer AG
    Full Title: A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma ov...
    Medical condition: Patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) BE (Completed) GB (Completed) ES (Completed) NL (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002762-12 Sponsor Protocol Number: MESOT-TREM-2012 Start Date*: 2012-06-29
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMANIZED ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA
    Medical condition: Patients affected by advanced malignant mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001121-24 Sponsor Protocol Number: P00804 Start Date*: 2011-04-21
    Sponsor Name:Papworth Hospital NHS Trust
    Full Title: Prospective randomised controlled trial of video assisted thorascopic (VATS) cytoreductive pleurectomy compared to talc pleurodesis in patients with suspected or proven malignant mesothelioma
    Medical condition: Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004273-28 Sponsor Protocol Number: EORTC 08031 Start Date*: 2005-11-15
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A phase II feasibility trial of induction chemotherapy followed by extrapleural pneumonectomy and postoperative radiotherapy in patients with malignant pleural mesothelioma.
    Medical condition: malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10029104 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001132-36 Sponsor Protocol Number: GOIRC-03-2016 Start Date*: 2016-10-03
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: A double-blind, placebo controlled, randomized multicenter Phase II Study evaluating Gemcitabine with or without Ramucirumab as II line treatment for advanced malignant pleural mesothelioma
    Medical condition: diffuse malignant pleural mesethelioma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000493-15 Sponsor Protocol Number: NVALT30 Start Date*: 2020-08-13
    Sponsor Name:Radboud University Medical Center
    Full Title: Dose tapering and Early Discontinuation to InCreAse cosT-effectIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1
    Medical condition: non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027412 Mesotheliomas HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005535-10 Sponsor Protocol Number: H3E-MC-JMHX(c) Start Date*: 2007-01-22
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 2 study of ALIMTA in solid tumor patients with stable third-space fluid
    Medical condition: either (1) relapsed, advanced (Stage III or IV) NSCLC or (2) malignant pleural or peritoneal mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-000521-38 Sponsor Protocol Number: EORTC-08112 Start Date*: 2017-06-30
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Nintedanib as maintenance treatment of malignant pleural mesothelioma (NEMO): a double-blind randomized phase II study of the EORTC Lung Cancer Group
    Medical condition: Malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035606 Pleural mesothelioma malignant localised LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000061-20 Sponsor Protocol Number: 20322 Start Date*: 2019-05-23
    Sponsor Name:Bayer AG
    Full Title: An open-label, multicenter rollover study to provide continued treatment with anetumab ravtansine for participants with solid tumors who were enrolled in previous Bayer-sponsored studies.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052747 Adenocarcinoma pancreas PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001160 Adenocarcinoma lung LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035605 Pleural mesothelioma malignant advanced LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073064 Epithelioid mesothelioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001515-23 Sponsor Protocol Number: PROICM2019-03MES Start Date*: 2020-01-29
    Sponsor Name:Institut Régional du Cancer de Montpellier
    Full Title: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma
    Medical condition: Patient with Histologically-confirmed diagnosis of peritoneal malignant mesothelioma and non eligible for cytoreductive surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002223-14 Sponsor Protocol Number: MPM2005 Start Date*: 2005-08-25
    Sponsor Name:Rigshospitalet
    Full Title: Fase II study of carboplatin and vinorelbine in malignant pleural mesothelioma
    Medical condition: Patients with malignant pleural mesothelioma who cannot be operated
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003633-16 Sponsor Protocol Number: D4200C00075 Start Date*: 2007-10-11
    Sponsor Name:AstraZeneca AB
    Full Title: A RANDOMIZED PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF VANDETANIB (ZD6474, ZACTIMATM) VERSUS VINORELBINE IN PATIENTS WITH INOPERABLE OR RELAPSED MALIGNANT MESOTHELIOMA
    Medical condition: Malignant mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004592-35 Sponsor Protocol Number: 6836 Start Date*: 2010-06-16
    Sponsor Name:Barts Health NHS Trust
    Full Title: A Randomised Stratified Multicentre Phase II Clinical Trial of Single-Agent ADI-PEG 20 (Pegylated Arginine Deiminase) in Patients with Malignant Pleural Mesothelioma.
    Medical condition: Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005033-16 Sponsor Protocol Number: ASTX295-01 Start Date*: 2022-12-07
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors
    Medical condition: Subjects with Wild-Type TP53 Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004388-37 Sponsor Protocol Number: 69HCL19_0457 Start Date*: 2020-03-03
    Sponsor Name:Hospices Civils de Lyon
    Full Title: A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural and Malignant Peritoneal MESOthelioma Pa...
    Medical condition: This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma. The cohorts B1 will be patient populations with non-resected or incomp...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    21.0 100000004864 10034669 Peritoneal mesothelioma malignant advanced LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001099-75 Sponsor Protocol Number: CCRG13-002 Start Date*: 2015-10-13
    Sponsor Name:Antwerp University Hospital
    Full Title: First-line immunotherapy using Wilms’ tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma.
    Medical condition: Treatment-naïve malignant pleural mesothelioma patients (eligible for standard chemotherapy and, in case of resectable disease, surgery)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 12:27:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA